Position in AKTS
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$17,046,379
New position
Shares Held
952,844
first reported quarter
Ownership
1.72%
of shares outstanding
% of Portfolio
5.39%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0.ToString("F0")%
Shared 100.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Merck & Co., Inc. holds $226,666,774 across 9 Biotechnology names. AKTS ranks #4 (7.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRNA |
Moderna, Inc.
|
2,308,190 | $117,256,052 | |
| 2 | KYMR |
Kymera Therapeutics, Inc.
|
772,165 | $64,313,622 | |
| 3 | EIKN |
Eikon Therapeutics, Inc.
|
1,666,666 | $17,633,326 | |
| 4 | AKTS |
Aktis Oncology, Inc.
This page
|
952,844 | $17,046,379 | |
| 5 | ALEC |
Alector, Inc.
|
3,545,719 | $7,623,295 | |
| 6 | VRDN |
Viridian Therapeutics, Inc.\DE
|
93,414 | $1,827,177 | |
| 7 | XLO |
Xilio Therapeutics, Inc.
|
105,982 | $891,308 | |
| 8 | NEUP |
Neuphoria Therapeutics Inc.
|
10,027 | $40,809 |
All Filings in AKTS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $17,046,379 | 952,844 | Shares | Defined | 2026-05-13 | |
| No filing history on record for this holder in this stock. | ||||||